Codexis [CDXS] vs Regeneron [REGN] Detailed Stock Comparison
Codexis
NASDAQ
Loading...
Regeneron
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Codexis wins in 6 metrics, Regeneron wins in 12 metrics, with 0 ties. Regeneron appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Codexis | Regeneron | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -2.82 | 14.64 | Codexis |
| Price-to-Book Ratio | 4.43 | 2.02 | Regeneron |
| Debt-to-Equity Ratio | 124.00 | 9.04 | Regeneron |
| PEG Ratio | 0.06 | 12.82 | Codexis |
| EV/EBITDA | -4.76 | 12.41 | Codexis |
| Profit Margin (TTM) | -113.67% | 31.37% | Regeneron |
| Operating Margin (TTM) | -83.91% | 29.64% | Regeneron |
| EBITDA Margin (TTM) | N/A | 29.64% | N/A |
| Return on Equity | -111.00% | 15.34% | Regeneron |
| Return on Assets (TTM) | -26.48% | 6.66% | Regeneron |
| Free Cash Flow (TTM) | $-53.72M | $3.54B | Regeneron |
| Dividend Yield | N/A | 0.46% | N/A |
| 1-Year Return | -11.68% | -49.87% | Codexis |
| Price-to-Sales Ratio (TTM) | 4.31 | 4.33 | Codexis |
| Enterprise Value | $249.08M | $55.45B | Regeneron |
| EV/Revenue Ratio | 4.36 | 3.90 | Regeneron |
| Gross Profit Margin (TTM) | 86.31% | 85.58% | Codexis |
| Revenue per Share (TTM) | $1 | $133 | Regeneron |
| Earnings per Share (Diluted) | $-0.80 | $39.66 | Regeneron |
| Beta (Stock Volatility) | 2.55 | 0.33 | Regeneron |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Codexis vs Regeneron Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Codexis | 0.41% | -11.03% | -14.79% | 3.86% | -9.70% | -51.60% |
| Regeneron | 0.61% | -2.14% | -0.76% | 16.97% | -16.03% | -20.69% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Codexis | -11.68% | -67.99% | -78.79% | -34.24% | -70.12% | -82.76% |
| Regeneron | -49.87% | -21.69% | 4.12% | 6.36% | 2,155.35% | 6,644.59% |
Performance & Financial Health Analysis: Codexis vs Regeneron
| Metric | CDXS | REGN |
|---|---|---|
| Market Information | ||
| Market Cap | $226.56M | $61.25B |
| Market Cap Category | Micro cap | Large cap |
| 10 Day Avg. Volume | 1,360,200 | 964,220 |
| 90 Day Avg. Volume | 1,167,960 | 972,393 |
| Last Close | $2.42 | $567.22 |
| 52 Week Range | $1.90 - $6.08 | $476.49 - $1,182.31 |
| % from 52W High | -60.20% | -52.02% |
| All-Time High | $42.01 (Nov 08, 2021) | $1,211.20 (Aug 26, 2024) |
| % from All-Time High | -94.24% | -53.17% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.92% | 0.04% |
| Quarterly Earnings Growth | 0.92% | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | -1.14% | 0.31% |
| Operating Margin (TTM) | -0.84% | 0.30% |
| Return on Equity (TTM) | -1.11% | 0.15% |
| Debt to Equity (MRQ) | 124.00 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.62 | $287.55 |
| Cash per Share (MRQ) | $0.74 | $72.04 |
| Operating Cash Flow (TTM) | $-61,218,000 | $4.74B |
| Levered Free Cash Flow (TTM) | $-45,006,500 | $2.85B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.46% |
| Last 12-Month Dividend | N/A | $2.64 |
Valuation & Enterprise Metrics Analysis: Codexis vs Regeneron
| Metric | CDXS | REGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -2.82 | 14.64 |
| Forward P/E | -3.96 | 12.82 |
| PEG Ratio | 0.06 | 12.82 |
| Price to Sales (TTM) | 4.31 | 4.33 |
| Price to Book (MRQ) | 4.43 | 2.02 |
| Market Capitalization | ||
| Market Capitalization | $226.56M | $61.25B |
| Enterprise Value | $249.08M | $55.45B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.36 | 3.90 |
| Enterprise to EBITDA | -4.76 | 12.41 |
| Risk & Other Metrics | ||
| Beta | 2.55 | 0.33 |
| Book Value per Share (MRQ) | $0.62 | $287.55 |
Financial Statements Comparison: Codexis vs Regeneron
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CDXS | REGN |
|---|---|---|
| Revenue/Sales | $15.33M | $3.03B |
| Cost of Goods Sold | $2.10M | $464.30M |
| Gross Profit | $13.23M | $2.56B |
| Research & Development | $13.78M | $1.34B |
| Operating Income (EBIT) | $-12.86M | $591.70M |
| EBITDA | $-10.21M | $900.90M |
| Pre-Tax Income | $-13.26M | $905.00M |
| Income Tax | $10,000 | $96.30M |
| Net Income (Profit) | $-13.27M | $808.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CDXS | REGN |
|---|---|---|
| Cash & Equivalents | $18.32M | $3.09B |
| Total Current Assets | $77.81M | $17.57B |
| Total Current Liabilities | $20.90M | $3.57B |
| Long-Term Debt | $56.58M | $2.70B |
| Total Shareholders Equity | $49.63M | $29.39B |
| Retained Earnings | $-583.49M | $32.38B |
| Property, Plant & Equipment | $64.18M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CDXS | REGN |
|---|---|---|
| Operating Cash Flow | $-13.39M | $1.36B |
| Capital Expenditures | $-1.26M | N/A |
| Free Cash Flow | $-15.05M | $773.60M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-1.05B |
Short Interest & Institutional Ownership Analysis
| Metric | CDXS | REGN |
|---|---|---|
| Shares Short | 5.19M | 2.35M |
| Short Ratio | 5.15 | 2.36 |
| Short % of Float | 0.06% | 0.02% |
| Average Daily Volume (10 Day) | 1,360,200 | 964,220 |
| Average Daily Volume (90 Day) | 1,167,960 | 972,393 |
| Shares Outstanding | 81.85M | 109.62M |
| Float Shares | 68.49M | 97.89M |
| % Held by Insiders | 0.02% | 0.02% |
| % Held by Institutions | 0.81% | 0.90% |
Dividend Analysis & Yield Comparison: Codexis vs Regeneron
| Metric | CDXS | REGN |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.64 |
| Last 12-Month Dividend Yield | N/A | 0.46% |
| 3-Year Avg Annual Dividend | N/A | $0.88 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | $2.64 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |